Accuray (ARAY) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
9 Nov, 2026Executive summary
FY18 net revenue rose 6% to $404.9M; gross margin expanded to 40% from 37%, and net loss narrowed to $23.9M from $29.6M.
Product backlog reached $478.5M, while net orders fell to $209.5M amid higher age-outs and cancellations; lengthy sales and installation cycles continue to make conversion uncertain.
Financial highlights
Product revenue increased 2% to $183.9M; services revenue rose 8% to $221.0M, driven by installed-base support, upgrades and spare parts.
Gross profit was $161.7M; product gross margin improved to 44% from 37%, while service gross margin was flat YoY.
Operating loss narrowed to $3.8M from $9.8M; net loss was $23.9M versus $29.6M, and diluted loss per share was $0.28 versus $0.36.
Operating cash flow was $18.3M versus cash use of $0.4M; cash and cash equivalents were $83.1M at June 30, 2018.
Product gross-margin improvement included an $8.0M decrease in acquired-intangible amortization, fully amortized in Q4 FY17; this comparison benefited FY18 reported results.
Outlook and guidance
FY19 R&D expense expected slightly below FY18; selling and marketing expense expected higher on product launches and added headcount; G&A expected relatively stable.
Existing cash, cash equivalents and investments were expected to fund working capital and capital expenditures for at least 12 months; additional financing may be needed if liquidity falls short.
Revenue under ASC 606 was expected to shift direct system sales toward recognition upon delivery, with installation deferred until performed; indirect sales and service recognition expected to remain unchanged.
Latest events from Accuray
- FY13 system-sales weakness and MLC delays drove losses despite service growth.ARAY
Q4 2013 - Revenue and orders rebounded; adjusted EBITDA turned positive, but execution risks remained.ARAY
Q4 2014 - Record Q4 orders and constant-currency gains were offset by FX pressure and execution risks.ARAY
Q4 2015 - Record backlog and $24.6M adjusted EBITDA marked progress despite a $25.5M net loss.ARAY
Q4 2016 - Record backlog and Radixact demand met lower revenue, weaker margins and continued losses.ARAY
Q4 2017 - TomoTherapy-led growth lifted revenue, but losses, cash use and conversion risks persisted.ARAY
Q4 2019 - Profitability returned, but COVID-19 delayed deliveries and backlog conversion.ARAY
Q4 2020 - Revenue grew 3%, but debt costs and COVID delays drove a $6.3m net loss.ARAY
Q4 2021 - Revenue grew, but margin compression and persistent cost pressures deepened the loss.ARAY
Q4 2023